MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial

Cognitive-behavioural conjoint therapy for PTSD (CBCT) is a manualised, empirically supported dyadic psychotherapy shown in prior studies to reduce PTSD symptoms, improve comorbid conditions, and enhance intimate partner functioning and partner well-being. Earlier research has also investigated MDMA (3,4-methylenedioxymethamphetamine) as a facilitator for individual psychotherapy for PTSD, reporting substantial symptom reductions and broader psychosocial benefits. However, MDMA had not previously been tested as an adjunct to an evidence-based, stand-alone relational therapy such as CBCT. Monson and colleagues set out to address this gap by conducting an initial, uncontrolled trial to assess the safety, tolerability, feasibility, and preliminary efficacy of MDMA-facilitated CBCT. The investigators hypothesised that combining MDMA with CBCT would be safe and feasible, and would produce significant and sustained improvements in PTSD, common comorbid symptoms, and relationship adjustment and happiness for both patients and their partners. The study targeted couples in which one partner met criteria for PTSD arising from a range of index traumas.

The trial received approval from relevant institutional review boards and the US Food and Drug Administration. Six heterosexual couples were enrolled in a condensed 15-session CBCT protocol delivered over 7 weeks; in each couple one partner met current PTSD criteria on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Inclusion criteria required participants to be aged 18 or older, generally medically healthy, English proficient, willing to refrain from psychiatric medications during the study, and to follow pre-session restrictions on food, drink and nicotine. Exclusion criteria included acute psychosis or mania, substance use disorder, pregnancy or nursing, or body weight under 48 kg. The extracted text reports the sample as all Caucasian, mean age about 47 years; among the patient participants four were male, most had multiple traumas, all had comorbid diagnoses and prior treatments, and 60% had previously received trauma-focused therapy. Treatment combined the full CBCT content with two MDMA-assisted dyadic sessions timed to align with key CBCT elements (communication skills first, cognitive processing later). The schedule began with an intensive weekend (sessions 1–3) before the first MDMA session, included in-person preparatory and morning-of content, a 6–8 hour MDMA session followed by a 1.5-hour integration session the next morning, a brief series of video sessions, a second intensive weekend with a second MDMA session and integration, and concluding weekly video sessions; the total treatment duration was 7 weeks. Dosing was 75 mg of MDMA for each partner in the first MDMA session and 100 mg in the second, with an optional supplemental half-dose 1.5 hours after the initial dose in both sessions. Therapies were co-delivered by clinicians experienced in MDMA-assisted therapy and in CBCT. Adverse events and spontaneous experiences were monitored throughout treatment and at 3- and 6-month follow-ups using standardised lists. Assessments occurred at pre-treatment, mid-treatment, post-treatment, and at 3- and 6-month follow-ups, with additional self- and partner-report measures taken at each treatment occasion. Primary clinician-rated outcome was CAPS-5; primary self-report outcomes were the PTSD Checklist (PCL-5) patient and partner versions and the Couples Satisfaction Index (CSI), including the single-item relationship happiness measure. Secondary measures included the Beck Depression Inventory-II (BDI-II), the Pittsburgh Sleep Quality Index, the Emotion Regulation Questionnaire (ERQ), and the Traumatic and Attachment Beliefs Scale. Independent assessors trained to reliability conducted clinician interviews. Overall assessment completion across self-report measures was 86%, and there were no missing clinician interviews for PTSD data. Analyses were performed in SPSS Version 26 using growth curve models with time transformed to the natural log of days since baseline. Given the small sample, slopes were fixed while intercepts were allowed to vary to account for different starting values. Within-group effect sizes (Cohen's d) from pre-treatment to each major assessment were calculated from model-estimated means and pooled raw standard deviations.

All six couples completed the full treatment protocol and there were no serious adverse events. Common acute reactions reported on the day of MDMA sessions included diminished appetite, anxiety, headache, and jaw tightness in both patients and partners. Clinician-assessed PTSD improved significantly over time (growth model B = -4.64, p < .001), with large within-group effect sizes at post-treatment and follow-ups (d = 1.88–2.25). According to clinician interview, all but one patient showed sustained remission of their PTSD diagnosis. Patient self-reported PTSD symptoms (PCL-5) also decreased significantly (B = -8.14, p < .001) with very large effect sizes (d ≈ 2.72–3.59), and partner-rated PCL-5 scores improved significantly (B = -5.90, p < .001) with large effects (d ≈ 1.85–2.72). Secondary patient outcomes showed significant improvement. Depressive symptoms decreased (B = -4.24) with effect sizes ranging from d = 1.50–2.53. Sleep quality improved (B = -0.81, p < .01; d = 0.88–1.18). Emotion regulation scores changed: reappraisal increased (B = 1.38, p < .01; d = 1.09–1.15) and suppression decreased (B = -1.12, p < .01; d = 1.12–1.20). Trauma-related beliefs improved (B = -12.01, p < .01; d = 0.98–1.17) at post-treatment and follow-ups. Regarding intimate relationship outcomes, growth models indicated significant gains in relationship satisfaction for both patients (B = 4.55, p < .05; d = 0.82–1.22) and partners (B = 5.73, p < .05; d = 0.64–0.80). Of the two patients classified as relationally distressed at baseline, both moved into the satisfied range at post-treatment and follow-ups. One patient who had been satisfied at baseline became dissatisfied at post-treatment and follow-ups; this same patient retained a PTSD diagnosis. Among three partners who were distressed at baseline, only one remained distressed at post-treatment and follow-ups, and this partner was paired with the patient who retained PTSD. The single-item relationship happiness measure also showed significant improvement for patients (B = 0.35, p < .001; d = 1.42–2.79) and partners (B = 0.33, p < .001; d = 1.30–1.78).

Monson and colleagues interpret these findings as preliminary evidence that MDMA can be safely integrated with an empirically supported dyadic therapy to facilitate improvements in PTSD and broader relational functioning. The investigators note this is the first trial to test MDMA alongside a stand-alone psychotherapy that is itself evidence-based outside of MDMA research. They report that the combined intervention appeared feasible, was not treatment-interfering, and produced large and sustained symptom reductions and relationship gains. The study team compared the observed effect sizes to prior reports: the PTSD effect sizes in this pilot exceeded pooled pre-to post-treatment effects reported for individually delivered MDMA-assisted psychotherapy in Phase II trials (pooled d ≈ 1.20), and were similar to or larger than outcomes previously reported for CBCT without MDMA. For example, a prior waitlist-controlled CBCT trial reported clinician-rated PTSD effects of g = 1.82 and smaller partner-rated relationship effects; in the present study clinician-rated PTSD effect was d = 2.10 and relationship effects for patient- and partner-rated measures were d = 0.82 and d ≈ 0.64, respectively. The authors further note that across outcomes effects were often largest at the 6-month follow-up, suggesting possible ongoing benefits following MDMA facilitation. The authors acknowledge substantial limitations that constrain inference. Foremost among these is the uncontrolled, non-randomised design and the very small sample, which preclude causal claims and reliable generalisation. Treatment was delivered by expert therapists in both MDMA and CBCT modalities, limiting applicability to broader clinical settings. The sample size prevented examination of moderators or mechanisms (for example, effects of patient/partner gender, baseline relationship distress, or trauma type). The investigators state that a Phase II randomised controlled trial is being prepared to more rigorously evaluate safety and efficacy and to address these outstanding questions. Finally, they position MDMA-facilitated CBCT as a potential avenue for innovation for individuals who do not respond to or tolerate existing frontline PTSD treatments and for expanding therapeutic targets to include intimate relationship functioning.